Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6904285 | 1.00 | HSD17B10 (0.36) | HSD17B10USP30PREPUCHL1NPC1 | |
| SCHEMBL6507574 | 0.86 | ATM (0.41) | HSD17B10USP30PREPUCHL1SMN1; SMN2 | |
| SCHEMBL5307511 | 0.86 | ATM (0.41) | HSD17B10USP30PREPUCHL1SMN1; SMN2 | |
| SCHEMBL25701906 | 0.82 | HSD17B10 (0.43) | HSD17B10USP30UCHL1NPC1SMN1; SMN2 | |
| SCHEMBL2096289 | 0.82 | HSD17B10 (0.43) | HSD17B10USP30UCHL1NPC1SMN1; SMN2 | |
| SCHEMBL444365 | 0.82 | HSD17B10 (0.43) | HSD17B10USP30UCHL1NPC1SMN1; SMN2 | |
| SCHEMBL18745636 | 0.81 | NR1H2 (0.42) | HSD17B10USP30PREPUCHL1NPC1 | |
| SCHEMBL337199 | 0.81 | NR1H2 (0.42) | HSD17B10USP30PREPUCHL1NPC1 | |
| SCHEMBL23982111 | 0.80 | HSD17B10 (0.41) | HSD17B10PREPUCHL1NPC1SMN1; SMN2 | |
| SCHEMBL1618739 | 0.80 | HSD17B10 (0.47) | HSD17B10PREPNPC1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326142-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326142-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326142-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-11-10 | — | — | US | disclosed |
| EP-2882718-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2015-06-17 | — | — | EP | disclosed |
| US-20150158851-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158851-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158851-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2014023258-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-02-13 | — | — | WO | disclosed |
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-04 | — | — | US | disclosed |
| EP-1368343-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002055518-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158851-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | CYP3A5, GLP1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HSD17B10 3217/4885USP30 4008/4885PREP 925/4885 |
| US-20160326142-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | CYP3A5, GLP1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HSD17B10 3217/4885USP30 4008/4885PREP 925/4885 |
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | BDKRB1, BDKRB2, TACR1 | HSD17B10 2498/4885USP30 4068/4885PREP 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.